Acute Bacterial Skin and Skin Structure Infections Market to Rise, 2034 | Cubist Pharmaceutical, Paratek Pharmaceutical, Menarini Group/Melinta Therapeutics, Durata Therapeutics, The Medicine Company, and others expected to boost the market

DelveInsight's "Acute Bacterial Skin and Skin Structure Infections - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Acute Bacterial Skin and Skin Structure Infections market share of the individual therapies, current and forecasted Acute Bacterial Skin and Skin Structure Infections market size from 2020 to 2034 segmented by seven major markets. The report also offers current Acute Bacterial Skin and Skin Structure Infections therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Bacterial Skin and Skin Structure Infections market.
Request for a Free Acute Bacterial Skin and Skin Structure Infections Market Sample Report @ https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key highlights from the acute bacterial skin and skin structure infections market report:
According to DelveInsight, the market for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) is projected to experience steady growth through 2034.

The epidemiology of ABSSSI is expected to expand due to several factors, including rising antibiotic resistance, an aging population, and an increase in invasive medical procedures, all contributing to higher incidence and prevalence rates.

While ABSSSI affects both genders, men are slightly more susceptible, likely due to occupational exposures, lifestyle factors, and hormonal influences. However, the specific reasons may vary based on individual and environmental risk factors.

ABSSSI can occur at any age, but older adults are often more vulnerable due to age-related changes in skin, underlying health conditions, and weakened immune systems, which make them more prone to bacterial infections and complications. Younger individuals, especially those with compromised immune systems or pre-existing medical conditions, can also be affected.

In July 2021, the U.S. Food and Drug Administration (FDA) approved AbbVie's DALVANCE (dalbavancin) for treating ABSSSI in pediatric patients from birth.

Market dynamics for ABSSSI are anticipated to evolve with the introduction of new treatment options, changes in regulatory policies, and shifts in healthcare spending priorities. These developments may lead to increased competition among pharmaceutical companies and improved patient outcomes.

Acute Bacterial Skin and Skin Structure Infections Overview
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) refer to a range of infections affecting the skin and its underlying structures, including subcutaneous tissue, fascia, and muscle. These infections can manifest as cellulitis, abscesses, or wound infections and often require prompt medical attention.

Causes
ABSSSI are primarily caused by bacterial pathogens, with the following being the most common:

Staphylococcus aureus (including Methicillin-resistant Staphylococcus aureus, MRSA)
Streptococcus pyogenes (Group A Streptococcus)
Escherichia coli
Pseudomonas aeruginosa (less common)
Risk factors include:

Breaks in the skin (cuts, abrasions, surgical wounds)
Poor hygiene
Chronic skin conditions (e.g., eczema)
Diabetes
Immunosuppression
Signs and Symptoms
The clinical presentation of ABSSSI may include:

Localized swelling and redness: The affected area may appear inflamed and warm.
Pain or tenderness: Patients often report discomfort at the infection site.
Fever: Systemic signs of infection may include fever and chills.
Pus or drainage: Abscesses may drain purulent material.
Lymphadenopathy: Swollen lymph nodes may occur nearby.
Diagnosis
Diagnosis typically involves:

Clinical evaluation: A thorough history and physical examination to assess the infection's extent and severity.
Laboratory tests: Blood tests may be performed to check for signs of infection (e.g., elevated white blood cell count). Cultures of pus or drainage can identify the causative organism.
Imaging studies: In some cases, ultrasound or CT scans may be used to evaluate deeper tissue involvement or abscess formation.
Treatment Options
Treatment for ABSSSI generally involves a combination of pharmacological and non-pharmacological approaches:

Antibiotics:

Empirical therapy may start with broad-spectrum antibiotics, especially for severe infections.
Common choices include:
Beta-lactam antibiotics (e.g., cephalexin)
MRSA coverage (e.g., vancomycin, linezolid)
Antibiotic therapy may be adjusted based on culture results and sensitivity patterns.
Drainage:

Surgical intervention may be necessary for abscesses or severe infections to drain pus and reduce pressure.
Supportive care:

Pain management with analgesics.
Keeping the affected area clean and covered.
Monitoring and follow-up:

Regular follow-up is essential to ensure the infection is resolving and to modify treatment if necessary.
Acute Bacterial Skin and Skin Structure Infections require prompt diagnosis and treatment to prevent complications. Early recognition and appropriate antibiotic therapy, along with possible surgical intervention, can lead to effective management and a favorable prognosis.

Learn more about Acute Bacterial Skin and Skin Structure Infections, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Acute Bacterial Skin and Skin Structure Infections Epidemiological Insights
The highest rate of MRSA hospitalizations occurs among the elderly, with 360.8 MRSA stays per 100,000 patients aged 65 and older. This rate is more than three times higher than any other age group: 114.7 stays for infants, 19.2 for those aged 1 to 17, 58.1 for individuals aged 18 to 44, and 111.5 for those aged 45 to 64 per 100,000.

According to secondary analysis, Acute Bacterial Skin and Skin Structure Infections (ABSSSI) accounted for nearly 870,000 hospital admissions in the United States in 2004, representing a 30% increase in incidence over four years. From 2005 to 2011, there was a 17.3% rise in hospital admissions for ABSSSI among nearly 5 million adults, with patients predominantly being male (50.8%), white (60.3%), and having a mean age of 55.7 years.

DelveInsight's analysis indicates that the incidence of ABSSSI is higher in men than in women. The most frequently isolated microorganisms from skin and soft tissue infections (SSTIs) include Staphylococcus aureus (29.2%), Pseudomonas aeruginosa (11.9%), E. coli (8.9%), and Enterococcus faecalis (7.4%).

Explore more about Acute Bacterial Skin and Skin Structure Infections Epidemiology at: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Acute Bacterial Skin and Skin Structure Infections Treatment Market
The treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) aims to relieve symptoms, improve quality of life, halt disease progression, and prevent recurrence. According to IDSA guidelines, initial management often involves oral antibiotics that are effective against streptococci for typical cellulitis cases. However, the rise of MRSA has necessitated a reassessment of treatment strategies. For mild cases of non-purulent infections, major treatment options include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin.

For ABSSSI with MRSA activity, both oral and intravenous options are available, including long-established therapies such as sulfamethoxazole-trimethoprim, clindamycin, minocycline, doxycycline, vancomycin, daptomycin, linezolid, ceftaroline, and telavancin. Antibiotics targeting MRSA are particularly considered for infections linked to penetrating trauma, such as intravenous drug use. The choice of antibiotic and treatment duration may vary based on severity, patient-specific factors, and resistance patterns.

In response to MRSA challenges, newer antibiotics like DALVANCE, ORBACTIV, and SIVEXTRO have been introduced. These agents offer extended dosing intervals due to their long half-lives, which can improve patient compliance and treatment outcomes. Their efficacy against MRSA makes them valuable additions to the ABSSSI treatment options.

Oritavancin, a lipoglycopeptide antibiotic, also presents a promising alternative. Its unique mechanism involves binding to the peptidoglycan precursor lipid II, leading to bacterial cell lysis. With a long half-life that allows for single-dose administration, oritavancin simplifies treatment regimens and enhances patient adherence. Its broad spectrum of activity, including effectiveness against MRSA, positions it as a significant tool in managing ABSSSI, with potential for improved patient outcomes and reduced healthcare burden.

Ongoing research and dedicated efforts hold promise for developing more effective treatments and, potentially, a cure for ABSSSI, a condition that presents numerous challenges. DelveInsight anticipates significant changes in the ABSSSI market across the 7MM from 2020 to 2034.


Request a sample and discover more about the Acute Bacterial Skin and Skin Structure Infections Market report offerings at:
https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Promising Therapies in the Acute Bacterial Skin and Skin Structure Infections Pipeline
● Sivextro
● Nuzyra
● Baxdela
● Dalbavancin
● Orbactiv
● And others
Request for a sample report to understand more about the Acute Bacterial Skin and Skin Structure Infections pipeline development activities at: https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Leading Companies Working in the Acute Bacterial Skin and Skin Structure Infections Market
● Cubist Pharmaceutical
● Paratek Pharmaceutical
● Menarini Group/ Melinta Therapeutics
● Durata Therapeutics
● The Medicine Company
● And others
To understand key companies related to the ABSSSI Market, get a snapshot of the Acute Bacterial Skin and Skin Structure Infections Regulatory and Patent Analysis @ https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Drug Overview
ABSSSI Marketed Drugs
DALVANCE (dalbavancin) - ABBVIE / Durata Therapeutics

DALVANCE (dalbavancin), developed by Durata Therapeutics, is a pioneering therapy for treating ABSSSI. Approved by the FDA in May 2014, DALVANCE is an intravenous, long-acting lipoglycopeptide antibiotic. Its mechanism targets cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of lipid II, a crucial precursor in this process. DALVANCE is effective against a wide range of Gram-positive bacteria, including MRSA and Streptococcus pyogenes, exhibiting strong bactericidal activity.

A key advantage of DALVANCE is its extended half-life, which allows for once-weekly dosing. This convenience simplifies treatment regimens and has the potential to enhance patient adherence, leading to improved clinical outcomes in managing ABSSSI.

ORBACTIV (oritavancin) - Melinta Therapeutics

ORBACTIV, developed by The Medicines Company (now part of Melinta Therapeutics), is a significant advancement in ABSSSI treatment. FDA-approved, it provides a novel strategy for tackling Gram-positive bacterial infections by inhibiting cell wall synthesis, specifically through binding to the peptidoglycan precursor lipid II. ORBACTIV demonstrates efficacy against various Gram-positive pathogens, including MRSA, and is distinguished by its unique pharmacokinetic profile that allows for once-daily dosing. This ease of administration can enhance patient compliance and improve clinical outcomes in ABSSSI management.

ABSSSI Emerging Drugs
The market for Acute Bacterial Skin and Skin-Structure Infections is expected to undergo gradual changes in the forecast period.

MRX-4 - MicuRx

MRX-4 is an injectable new oxazolidinone antibacterial agent designed to treat multidrug-resistant (MDR) infections. It exhibits potent activity against Gram-positive bacteria, including MRSA, vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP). In September 2018, the US FDA granted qualified infectious disease product (QIDP) status and fast track designation to contezolid acefosamil for treating ABSSSI. The drug is currently in Phase III clinical development.

ZEVTERA (ceftobiprole) - Basilea Pharmaceutica

ZEVTERA, developed by Basilea Pharmaceutica, is an intravenous cephalosporin antibiotic that exhibits rapid bactericidal activity against a broad spectrum of bacteria, including MSSA, MRSA, and susceptible Pseudomonas species. It is currently approved for treating hospital-acquired pneumonia. In August 2019, positive topline results from the TARGET study were reported, followed by favorable outcomes from the ERADICATE study in June 2022. In April 2024, the US FDA granted approval for the New Drug Application (NDA) of ceftobiprole, which includes indications for treating Staphylococcus aureus bacteremia (SAB), right-sided infective endocarditis, ABSSSI, and community-acquired bacterial pneumonia (CABP).

Scope of the Acute Bacterial Skin and Skin Structure Infections Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute Bacterial Skin and Skin Structure Infections Companies: Cubist Pharmaceutical, Paratek Pharmaceutical, Menarini Group/ Melinta Therapeutics, Durata Therapeutics, The Medicine Company, and others
Key Acute Bacterial Skin and Skin Structure Infections Pipeline Therapies: Sivextro, Nuzyra, Baxdela, Dalbavancin, Orbactiv, and others
Therapeutic Assessment: Acute Bacterial Skin and Skin Structure Infections current marketed and emerging therapies
Acute Bacterial Skin and Skin Structure Infections Market Dynamics: Acute Bacterial Skin and Skin Structure Infections market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute Bacterial Skin and Skin Structure Infections Market Access and Reimbursement
Table of Contents
1. Acute Bacterial Skin and Skin Structure Infections Market Key Insights
2. Acute Bacterial Skin and Skin Structure Infections Market Report Introduction
3. Acute Bacterial Skin and Skin Structure Infections Market Overview at a Glance
4. Acute Bacterial Skin and Skin Structure Infections Market Executive Summary
5. Disease Background and Overview
6. Acute Bacterial Skin and Skin Structure Infections Treatment and Management
7. Acute Bacterial Skin and Skin Structure Infections Epidemiology and Patient Population
8. Patient Journey
9. Acute Bacterial Skin and Skin Structure Infections Emerging Drugs
10. 7MM Acute Bacterial Skin and Skin Structure Infections Market Analysis
11. Acute Bacterial Skin and Skin Structure Infections Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute Bacterial Skin and Skin Structure Infections Market Drivers
15. Acute Bacterial Skin and Skin Structure Infections Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us
Name: Kritika Rehani
E-mail: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.